Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Proposal of a new grading system for meningioma resection: the Copenhagen Protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Diagnostic Accuracy and Clinical Impact of [ 18F]FET PET in Childhood CNS tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Associations between oxidative stress and perceived stress in patients with bipolar disorder and healthy control individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The two biomarkers 2-[18F]FDG-PET and cerebrospinal fluid biomarkers are both recommended to support the diagnosis of Alzheimer's disease. However, there is a lack of knowledge for the comparison of the two biomarkers in a routine clinical setting.

OBJECTIVE: The aim was to compare the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers on diagnosis, prognosis, and patient management in patients suspected of Alzheimer's disease.

METHODS: Eighty-one patients clinically suspected of Alzheimer's disease were retrospectively included from the Copenhagen Memory Clinic. As part of the clinical work-up all patients had a standard diagnostic program examination including MRI and ancillary investigations with 2-[18F]FDG-PET and cerebrospinal fluid biomarkers. An incremental study design was used to evaluate the clinical impact of the biomarkers. First, the diagnostic evaluation was based on the standard diagnostic program, then the diagnostic evaluation was revised after addition of either cerebrospinal fluid biomarkers or 2-[18F]FDG-PET. At each diagnostic evaluation, two blinded dementia specialists made a consensus decision on diagnosis, prediction of disease course, and change in patient management. Confidence in the decision was measured on a visual analogue scale (0-100). After 6 months, the diagnostic evaluation was performed with addition of the other biomarker. A clinical follow-up after 12 months was used as reference for diagnosis and disease course.

RESULTS: The two biomarkers had a similar clinical value across all diagnosis when added individually to the standard diagnostic program. However, for the correctly diagnosed patient with Alzheimer's disease cerebrospinal fluid biomarkers had a significantly higher impact on diagnostic confidence (mean scores±SD: 88±11 vs. 82±11, p = 0.046) and a significant reduction in the need for ancillary investigations (23 vs. 18 patients, p = 0.049) compared to 2-[18F]FDG-PET.

CONCLUSION: The two biomarkers had similar clinical impact on diagnosis, but cerebrospinal fluid biomarkers had a more significant value in corroborating the diagnosis of Alzheimer's disease compared to 2-[18F]FDG-PET.

Original languageEnglish
Article numbere0248413
JournalPLoS One
Volume16
Issue number3
Pages (from-to)e0248413
ISSN1932-6203
DOIs
Publication statusPublished - 2021

    Research areas

  • Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Female, Fluorodeoxyglucose F18/administration & dosage, Follow-Up Studies, Humans, Male, Middle Aged, Positron-Emission Tomography, Retrospective Studies

ID: 68395914